<DOC>
	<DOCNO>NCT00639119</DOCNO>
	<brief_summary>The progressive myoclonus epilepsy Unverricht-Lundborg disease ( ULD ) type autosomal recessive disease characterize progressive stimulus-sensitive action-related myoclonic jerk . The mainstay current treatment myoclonic epilepsy include ULD valproic acid clonazepam among several antiepileptic drug . Unfortunately disease may often resistant antiepileptic drug lead major reduction daily activity disability walk without assistance . Therefore new treatment modality need . Experimental treatment ULD patient dopamine agonist relieve myoclonic symptom . Further , accordance , recent study indicate decrease dopaminergic neurotransmission basal ganglion ULD patient , determine PET . The purpose study investigate effect dopaminergic medication ( ropinirole hydrochloride , Requip Â® ) relieve symptom ULD patient . Patients undergo sixteen week intervention period . The main efficacy determinant change unify myoclonus rating scale ( UMRS ) , nerve conduction , multi-modality evoked potential include visual evoke potential ( VEP ) , somatosensory evoke potential ( SSEP ) brainstem auditory evoke potential ( BAEP ) , blink reflex habituation electroencephalography ( EEG ) . Tolerability safety medication determine . The study set placebo control , crossover , two-group double blind study .</brief_summary>
	<brief_title>Effect Ropinirole Hydrochloride Progressive Myoclonic Epilepsy Unverricht-Lundborg Type</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Myoclonic</mesh_term>
	<mesh_term>Myoclonic Epilepsies , Progressive</mesh_term>
	<mesh_term>Unverricht-Lundborg Syndrome</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<criteria>UnverrichtLundborg Syndrome Pregnancy Intolerability ropinirole hydrochloride Mental illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2008</verification_date>
</DOC>